WO2002089757A2 - Utilisation d'isoflavones dans des preparations cosmetiques ou dermatologiques - Google Patents

Utilisation d'isoflavones dans des preparations cosmetiques ou dermatologiques Download PDF

Info

Publication number
WO2002089757A2
WO2002089757A2 PCT/EP2002/004624 EP0204624W WO02089757A2 WO 2002089757 A2 WO2002089757 A2 WO 2002089757A2 EP 0204624 W EP0204624 W EP 0204624W WO 02089757 A2 WO02089757 A2 WO 02089757A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
isoflavone
hydroxy
cosmetic
dihydro
Prior art date
Application number
PCT/EP2002/004624
Other languages
German (de)
English (en)
Other versions
WO2002089757A3 (fr
Inventor
Helga Biergiesser
Stefan Gallinat
Andreas Herpens
Kirsten Venzke
Uwe SCHÖNROCK
Franz STÄB
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of WO2002089757A2 publication Critical patent/WO2002089757A2/fr
Publication of WO2002089757A3 publication Critical patent/WO2002089757A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • the present invention relates to the use of special isoflavonoids in cosmetic or dermatological preparations for the prophylaxis before and treatment of sensitive skin, itching and changes in the DNA synthesis and / or DNA repair performance in the skin.
  • the present invention relates to cosmetic preparations with additional, effective protection against harmful oxidation processes in the skin, but also for additional protection of cosmetic preparations themselves or for additional protection of the constituents of cosmetic preparations against harmful oxidation processes.
  • Cosmetic skin care is primarily to be understood to mean that the natural function of the skin acts as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, natural fats, electrolytes) is strengthened or restored.
  • environmental influences e.g. dirt, chemicals, microorganisms
  • loss of the body's own substances e.g. water, natural fats, electrolytes
  • the aim of skin care is also to compensate for the loss of fat and water in the skin caused by daily washing. This is especially important when the natural regeneration ability is insufficient.
  • skin care products are said to exist
  • the chronological skin aging is e.g. B. caused by endogenous, genetically determined factors.
  • the epidermis and dermis it occurs due to aging e.g. B. the following structural damage and malfunctions, which may also fall under the term "senile xerosis":
  • Exogenous factors such as UV light and chemical pollutants, can be cumulatively effective.
  • exogenous factors e.g. B.
  • Products for the care of sensitive, itchy and / or dry skin or products for the treatment of or prophylaxis against DNA damage are known per se. However, their effectiveness is limited.
  • UVC range rays with a wavelength shorter than 290 nm
  • UVB range rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema simple sunburn or even more or less severe burns.
  • the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
  • UVA range It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation leads to damage to the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
  • Such photochemical reaction products are predominantly free radical compounds, for example hydroxy radicals.
  • Undefined radical-free photo products that arise in the skin itself can also display uncontrolled subsequent reactions due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others.
  • Singlet oxygen for example, is characterized by increased reactivity compared to the triplet oxygen normally present (radical ground state). However, there are also excited, reactive (radical) triplet states of the oxygen molecule.
  • UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV rays, which in turn can oxidatively intervene in the biochemical processes.
  • antioxidants and / or free radical scavengers can be incorporated into the cosmetic or dermatological formulations. It has already been proposed to use vitamin E, a substance with a known antioxidative effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the object of the invention was therefore to provide cosmetic, dermatological and pharmaceutical active substances and preparations and light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses, preferably polymorphic light dermatosis.
  • Antioxidants are mainly used as protective substances against the spoilage of the preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin.
  • antioxidants and / or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
  • antioxidants and radical scavengers are known.
  • US Pat. Nos. 4,144,325 and 4,248,861 as well as numerous other documents, have proposed the use of vitamin E, a substance with a known antioxidant activity in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • Another object of the present invention was therefore to address the disadvantages of the prior art the technology and in particular to permanently or sustainably eliminate the damage caused by environmental noxious substances without the risk of side effects or to prevent them.
  • Ipriflavone (7-isopropoxy-isoflavone), formononetin (7-hydroxy-4 '-Methoxyiso- flavone), ononin (formononetin-7-O-ß-D-glucopyranoside), 4' -lsopropy!
  • Cosmetic or dermatological preparations according to the invention preferably contain 0.001 to 10% by weight, particularly preferably 0.01 to 1% by weight, of isoflavones, based on the total composition of the preparations.
  • preparations containing the active compound combinations according to the invention, customary antioxidants can be used.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. uro- canic acid) and their derivatives, peptides such as D, L-camosin, D-camosin, L-camosin and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. carotene, ß-carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. uro- canic acid
  • peptides such as D, L-camosin,
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, Ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, Lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfoximines homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, heptathioninsulfoximine) in very low tolerable dosages (e.g. pmol to ⁇ mol / kg), furthermore (metal) chelators (eg ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lacto fe ⁇ in), ⁇ -hydroxy acids (e.g. B.
  • metal chelators eg ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lacto fe ⁇ in
  • ⁇ -hydroxy acids e.g. B.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives Alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g.
  • vitamin E acetate vitamin E acetate
  • coniferyl benzoate of the benzoin resin Rutinic acid and its derivatives, ferulic acid and its derivatives, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (e.g. ZnO, ZnSO) selenium and its derivatives.
  • stilbenes and their derivatives for example stilbene oxide, trans-stilbene oxide
  • derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, nu kleoside, peptides and lipids
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
  • the active compounds according to the invention for. B. as a so-called solid lipid nanoparts with the help of melted waxes, which, among other things, but not exclusively, can be selected from the group of ester waxes, triglyceride waxes or hydrocarbon waxes. Furthermore, it can be from It is advantageous to encapsulate the active compounds according to the invention in polymers, for. B. in particles based on highly cross-linked polymethacrylates and / or cellulose triacetates and / or as core / shell particles with a shell made of poly (oxymethylurea), nylon, polyamides, polyurethane, polyester, gelatin and polyolefins.
  • polymers for. B. in particles based on highly cross-linked polymethacrylates and / or cellulose triacetates and / or as core / shell particles with a shell made of poly (oxymethylurea), nylon, polyamides, polyurethane, polyester, gelatin and polyolefins.
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is carried out in the usual way, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of the active ingredient used according to the invention are applied to the affected skin areas.
  • the active ingredient used according to the invention can advantageously be incorporated into conventional cosmetic and dermatological preparations, which can be in various forms. So you can z. B. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in -Water (W / O / W) or oil-in-water-in-oil (OW / O), a hydrodispersion or lipodispersion, a gel, a Pickering emulsion, a solid stick or an aerosol.
  • W / O type water-in-oil
  • O / W oil-in-water
  • OW / O oil-in-water-in-oil
  • Emulsions according to the invention in the sense of the present invention for. B. in the form of a cream, a lotion, a cosmetic milk are advantageous and contain z.
  • compositions are usually inconceivable without the customary auxiliaries and additives.
  • auxiliaries and additives include, for example, consistency agents, fillers, perfume, dyes, emulsifiers other active ingredients such as vitamins or proteins, light stabilizers, stabilizers, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytically active substances etc.
  • Medical topical compositions in the sense of the present invention generally contain one or more medicaments in an effective concentration.
  • medicaments in an effective concentration.
  • cosmetic or topical dermatological compositions within the meaning of the present invention, depending on their structure, can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to use the compositions according to the invention as a basis to use for pharmaceutical formulations.
  • UV-A or UV-B filter substances are usually incorporated into day creams or makeup products. UV protection substances, like antioxidants and, if desired, preservatives, also provide effective protection of the preparations themselves against spoilage.
  • cosmetic and dermatological preparations which are in the form of a sunscreen are favorable.
  • the preparations preferably contain, in addition to one or more active ingredients used according to the invention, at least one further UV-A and / or UV-B filter substance.
  • the formulations can, although not necessary, optionally also contain one or more organic and / or inorganic pigments as UV filter substances, which may be present in the water and / or the oil phase.
  • Preferred inorganic pigments are metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular oxides of titanium (TiO 2 ), zinc (ZnO), iron (e.g. Fe 2 O 3 ), zirconium (ZrO 2 ), silicon ( SiO 2 ), manganese (e.g. MnO), aluminum (Al 2 0 3 ), cerium (e.g. Ce 2 ⁇ 3), mixed oxides of the corresponding metals and mixtures of such oxides.
  • such pigments can advantageously be surface-treated (“coated”), with an amphiphilic or hydrophobic character, for example, being formed or maintained be provided with a hydrophobic layer.
  • z. B titanium dioxide pigments coated with octylsilanol. Suitable titanium dioxide particles are available under the trade name T805 from Degussa. Also particularly advantageous are TiO 2 pigments coated with aluminum stearate, e.g. B. those available under the trade name MT 100 T from TAYCA.
  • Another advantageous coating of the inorganic pigments consists of dimethyl polysiloxane (also: dimethicone), a mixture of fully methylated, linear siloxane polymers which are blocked at the end with trimethylsiloxy units.
  • Zinc oxide pigments which are coated in this way are particularly advantageous for the purposes of the present invention.
  • the inorganic pigments are also advantageous to coat with a mixture of dimethylpolysiloxane, in particular dimethylpolysiloxane with an average chain length of 200 to 350 dimethylsiloxane units, and silica gel, which is also known as Simethicone is called. It is particularly advantageous if the inorganic pigments are additionally coated with aluminum hydroxide or aluminum oxide hydrate (also: alumina, CAS no .: 1333-84-2). Titanium dioxides which are coated with simethicone and alumina are particularly advantageous, the coating also being able to contain water. An example of this is the titanium dioxide available from Merck under the trade name Eusolex T2000.
  • An advantageous organic pigment for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1, 1, 3,3-tetramethyl! Butyl) - phenol) [INCI: bisoctyl-triazole], which is available under the trade name Tinosorb® M from CIBA-Chemicals GmbH.
  • Preparations according to the invention advantageously contain substances which absorb UV radiation in the UV-A and / or UV-B range, the total amount of the filter substances, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to cosmetic
  • 0.1 wt .-% to 30 wt .-% preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to cosmetic
  • preparations that protect the hair or skin from the entire range of ultraviolet radiation They can also serve as a sunscreen for the hair or skin.
  • UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • dibenzoyl methane derivatives in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • UV-A filter substances are the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and its salts, especially the corresponding sodium, potassium or triethanolammonium salts , in particular the phenylene-1,4-bis (2-benzimizazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt with the INCI name bisimidazylate, which, for example, under the trade name Neo Heliopan AP is available from Haarmann & Reimer.
  • 1,4-di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene and its salts especially the corresponding 10-sulfato compounds, especially the corresponding speaking sodium, potassium or triethanolammonium salt, which is also referred to as benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid).
  • Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, i.e. Filter substances that absorb both UV-A and UV-B radiation.
  • Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives.
  • This is particularly preferred 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1,3,5-triazine (INCl: Aniso Triazin), which is available under the trade name Tinosorb® S from CIBA-Chemicals GmbH.
  • Particularly advantageous preparations in the sense of the present invention which are distinguished by a high or very high UV-A protection, preferably contain a plurality of UV-A and / or broadband filters, in particular dibenzoylmethane derivatives [for example 4- (tert-butyl) -4'-methoxydibenzoylmethane], benzotriazole derivatives [e.g.
  • UV filter substances which the structural motif
  • R represents a branched or unbranched CrC, 8 alkyl radical, a C 5 -C 2 cycloalkyl radical, optionally substituted with one or more CC 4 alkyl groups,
  • X represents an oxygen atom or an NH group, i a branched or unbranched CrCis alkyl radical, a C 5 -C 2 cycloalkyl radical, optionally substituted with one or more CC 4 alkyl groups, or a hydrogen atom, an alkali metal atom, one Ammonium group or a group of formula
  • A represents a branched or unbranched CrC 18 alkyl radical, a C 1 -C 2 cycloalkyl or aryl radical, optionally substituted by one or more C 1 -C 4 alkyl groups,
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10
  • R 2 represents a branched or unbranched CrC 18 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more dC 4 alkyl groups, when X represents the NH group, and a branched or unbranched CrC ⁇ 8 -Alkyl radical, a C 5 -C 2 cycloalkyl radical, optionally substituted with one or more C 1 -C 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched C 1 -C 8 -alkyl radical, a C 5 -C 2 -cycloalkyl or aryl radical, optionally substituted with one or more CC 4 alkyl groups,
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10 when X represents an oxygen atom.
  • a particularly preferred UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula
  • dioctylbutylamidotriazon IRCl: dioctylbutamidotriazone
  • UVASORB HEB trade name UVASORB HEB from Sigma 3V.
  • a symmetrically substituted s-triazine which is 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2- ethylhexyl ester), synonym: 2,4,6-tris- [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCl: Oetyl Triazone), which is marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150.
  • R t , R 2 and Ai represent a wide variety of organic radicals.
  • Also advantageous in the sense of the present invention are the 2,4-bis - ⁇ [4- (3-sulfonato) - 2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine sodium salt, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl ) -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- [4- (2-methoxyethyl carboxyl ) -phenylamino] -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ - 6- [4
  • An advantageous broadband filter for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) , which is available under the trade name Tinosorb® M from CIBA-Chemicals GmbH.
  • Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane.
  • the UV-B and / or broadband filters can be oil-soluble or water-soluble.
  • Advantageous oil-soluble UV-B and / or broadband filter substances are e.g. B .:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester
  • ⁇ esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester
  • Advantageous water-soluble UV-B and / or broadband filter substances are e.g. B .:
  • ⁇ salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself
  • ⁇ sulfonic acid derivatives of 3-benzylidene camphor such as.
  • a further light protection filter substance according to the invention to be used advantageously is ethylhexyl-2-cyano-3,3-diphenylacrylate, obtainable (Octoerylen) from BASF under the name Uvinul ® N 539th
  • the preparations according to the invention advantageously contain the substances which absorb UV radiation in the UV-A and / or UV-B range in a total amount of, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1, 0 to 15.0 wt .-%, each based on the total weight of the preparations to cosmetics - see preparations that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic active ingredients, auxiliaries and / or additives, as are usually used in such preparations, e.g. B. antioxidants, preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common ingredients a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic active ingredients e.g. B. antioxidants, preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common ingredients
  • the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
  • oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. B. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids; • Alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analog products.
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobuty
  • Water can also be a component of alcoholic solvents.
  • the group of esters is advantageously chosen from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl ethylhexyl palate 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate and synthetic, semi-synthetic and natural mixtures of such esters, e.g. B. Jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semi-synthetic and natural oils, e.g. B. olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldecanol, isotridecyl isononanoate, isoeieosan, 2-ethylhexyl cocoate, C 2- 2- alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C 12- ⁇ s benzoate and 2-Ethylhexylisostea- rat, mixtures of C ⁇ 2 . ⁇ 5 -alkyl benzoate and isotridecyl isononanoate and mixtures from C ⁇ 2 .i5-alkylbenzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention.
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols with a low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethylenglykolmonomethyl- or - onoethylether and analogous products, furthermore low C-number alcohols, e.g.
  • isopropanol, 1,2-propanediol, glycerol and in particular one or more thickening agents which or which can advantageously be selected from the group silicon dioxide, aluminum silicates, polysaccharides or their derivatives, eg. B. hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose, particularly advantageously from the group of polyaerylates, preferably a polyacrylate from the group of so-called carbopoles, for example carbopoles of types 980, 981, 1382, 2984, 5984, each individually or in combination.
  • thickening agents which or which can advantageously be selected from the group silicon dioxide, aluminum silicates, polysaccharides or their derivatives, eg. B. hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose, particularly advantageously from the group of polyaerylates, preferably a polyacrylate from the group of so-called carbopoles, for example carbopoles
  • Gels used according to the invention usually contain low C-number alcohols, e.g. As ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener, which is used in oily alcoholic gels preferably silicon dioxide or an aluminum silicate, preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
  • low C-number alcohols e.g. As ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener, which is used in oily alcoholic gels preferably silicon dioxide or an aluminum silicate, preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
  • Fixed pens contain e.g. B. natural or synthetic waxes, fatty alcohols or fatty acid esters.
  • liquid oils e.g. paraffin oils, castor oil, isopropyl myristate
  • semi-solid components e.g. petroleum jelly, lanolin
  • solid components e.g. beeswax, ceresin and microcrystalline waxes or ozokerite
  • high-melting waxes e.g. camauba wax, candelilla wax
  • Suitable blowing agents for cosmetic and / or dermatological preparations sprayable from aerosol containers for the purposes of the present invention are the customary known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another , Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • Cosmetic preparations within the meaning of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents usually used for this purpose, preferably water, or organic thickeners, for.
  • the thickener is in the gel e.g. B.
  • the cosmetic or dermatological preparations according to the invention contain further active substances, in particular natural active substances and / or their derivatives, such as, for example, B. alpha-lipoic acid, phytoene, D-biotin, coenzyme Q10, alpha glucosylrutin, carnitine, carnosine, osmolytes, clover extract, hop or hop malt extract.
  • active substances such as, for example, B. alpha-lipoic acid, phytoene, D-biotin, coenzyme Q10, alpha glucosylrutin, carnitine, carnosine, osmolytes, clover extract, hop or hop malt extract.
  • the content of these active ingredients is advantageously chosen from the range from 0.0001 to 30% by weight, based on the total weight of the preparations.
  • isoflavones here in particular one or more of the following substances: ipriflavone (7-isopropoxy-isoflavone), formononetin (7-hydroxy-4 '-Methoxyisoflavon) ononin ( formononetin-7-O-ß-D-glucopyranoside), 4 '-lsopropyl isoflavone, mono-hydroxy-isoflavones, mono-hydroxy-dihydro-isoflavones, mono-hydroxy-tetrahydro-isoflavones, O- desmethylangolensin, dihydro-daidzein ( dihydro-7,4 '-dihydroxy isoflavone), tetrahydro-daidzein (tetrahydro-7,4' -dihydroxy isoflavone), genistein dihydro-(dihydro-5,7,4 '-tri- hydroxy isoflavone), genistein dihydro-(dihydro-5

Abstract

L'invention concerne l'utilisation de substances sélectionnées dans le groupe comprenant : ipriflavone (7-isopropoxy-isoflavone), formononétine (7-hydroxy-4'-méthoxy-isoflavone), ononine (formononétine-7-O-β-D-glucopyranoside), 4'-isopropyl-isoflavone, monohydroxy-isoflavone, monohydroxy-dihydro-isoflavone, monohydroxy-tétrahydro-isoflavone, O-desméthylangolensine, dihydro-daidzéine (dihydro-7,4'-dihydroxy-isoflavone), tétrahydro-daidzéine (tétrahydro-7,4'-dihydroxy-isoflavone), dihydro-génistéine (dihydro-5,7,4'-trihydroxy-isoflavone), 2-déhydro-O-desméthylangolensine, déhydro-équol, 4-hydroxy-7-glucose-isoflavone et 5-hydroxy-7,4'-diméthoxy-isoflavone, dans des préparations cosmétiques ou dermatologiques pour le traitement et la prophylaxie des symptômes d'inflammations ou de démangeaisons de la peau, de sensibilité de la peau, et de modifications de la synthèse d'ADN et/ou de la réparation d'ADN dans la peau.
PCT/EP2002/004624 2001-05-09 2002-04-26 Utilisation d'isoflavones dans des preparations cosmetiques ou dermatologiques WO2002089757A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2001122342 DE10122342A1 (de) 2001-05-09 2001-05-09 Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen
DE10122342.0 2001-05-09

Publications (2)

Publication Number Publication Date
WO2002089757A2 true WO2002089757A2 (fr) 2002-11-14
WO2002089757A3 WO2002089757A3 (fr) 2003-03-13

Family

ID=7684041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004624 WO2002089757A2 (fr) 2001-05-09 2002-04-26 Utilisation d'isoflavones dans des preparations cosmetiques ou dermatologiques

Country Status (2)

Country Link
DE (1) DE10122342A1 (fr)
WO (1) WO2002089757A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534232A1 (fr) * 2002-09-06 2005-06-01 Novogen Research Pty. Ltd. Reparation de dommages mutagenes d'adn
EP1542654A1 (fr) * 2002-09-23 2005-06-22 Novogen Research Pty. Ltd. Traitement du photovieillissement et de la deterioration actinique de la peau
EP1676571A1 (fr) * 2004-12-08 2006-07-05 Beiersdorf AG Composition comprenant au moins un isoflavone et du carnitine et/ ou au moins un acyl-carnitine
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
CN108261376A (zh) * 2018-03-06 2018-07-10 森知（上海）国际贸易有限公司 一种三维保湿因子
CN109053667A (zh) * 2018-08-02 2018-12-21 山东大学 一种异黄酮衍生物的分离方法及应用
EP3868360A4 (fr) * 2018-10-15 2022-08-10 Amorepacific Corporation Composition pour inhiber l'activation d'un récepteur des minéralocorticoïdes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10301631A1 (de) * 2003-01-17 2004-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Sojabohnenkeimextrakten in Kombination mit Vitamin C und/oder E sowie alpha-Glycosylrutin
KR102264451B1 (ko) * 2019-11-22 2021-06-14 오산대학교 산학협력단 Pka 단백질 키나제 억제제로서의 이프리플라본을 포함하는 미백용 조성물, 이를 함유하는 화장품 및 의약 조성물, 그리고 이의 제조 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056373A1 (fr) * 1997-06-11 1998-12-17 Gorbach Sherwood L Isoflavonoïde utilise pour traiter et prevenir le vieillissement de la peau et les rides
WO1999036050A1 (fr) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions et procede pour la protection de la peau contre une immuno-suppression ou des lesions provoquees par les rayons uv

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001213775A (ja) * 2000-02-03 2001-08-07 Pola Chem Ind Inc ストレス軽減剤及びそれを含有してなる皮膚外用剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056373A1 (fr) * 1997-06-11 1998-12-17 Gorbach Sherwood L Isoflavonoïde utilise pour traiter et prevenir le vieillissement de la peau et les rides
WO1999036050A1 (fr) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions et procede pour la protection de la peau contre une immuno-suppression ou des lesions provoquees par les rayons uv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; Accession Number 2001:573233, POLA CHEMICAL INDUSTRIES: "Skin stress-decreasing compositions containing isoflavone or flavone derivatives" XP002212265 & JP 2001 213775 A (POLA CHEMICAL INDUSTRUES) 7. August 2001 (2001-08-07) *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048913B2 (en) 2002-07-24 2011-11-01 Australian Health & Nutrition Assoc. Ltd. Compositions and products containing S-equol, and methods for their making
US9408824B2 (en) 2002-07-24 2016-08-09 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9018247B2 (en) 2002-07-24 2015-04-28 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US7960432B2 (en) 2002-07-24 2011-06-14 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
EP1534232A4 (fr) * 2002-09-06 2008-12-24 Novogen Res Pty Ltd Reparation de dommages mutagenes d'adn
EP1534232A1 (fr) * 2002-09-06 2005-06-01 Novogen Research Pty. Ltd. Reparation de dommages mutagenes d'adn
EP1542654A1 (fr) * 2002-09-23 2005-06-22 Novogen Research Pty. Ltd. Traitement du photovieillissement et de la deterioration actinique de la peau
EP1542654A4 (fr) * 2002-09-23 2008-12-17 Novogen Res Pty Ltd Traitement du photovieillissement et de la deterioration actinique de la peau
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US9089547B2 (en) 2002-10-29 2015-07-28 Brigham Young University Use of equol for treating androgen mediated diseases
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US9889116B2 (en) 2002-10-29 2018-02-13 Bringham Young University Use of equol for treating androgen mediated diseases
US10111855B2 (en) 2002-10-29 2018-10-30 Brigham Young University Use of equol for treating androgen mediated diseases
EP1676571A1 (fr) * 2004-12-08 2006-07-05 Beiersdorf AG Composition comprenant au moins un isoflavone et du carnitine et/ ou au moins un acyl-carnitine
CN108261376A (zh) * 2018-03-06 2018-07-10 森知（上海）国际贸易有限公司 一种三维保湿因子
CN108261376B (zh) * 2018-03-06 2021-01-12 上海科颜生物科技有限公司 一种三维保湿因子
CN109053667A (zh) * 2018-08-02 2018-12-21 山东大学 一种异黄酮衍生物的分离方法及应用
EP3868360A4 (fr) * 2018-10-15 2022-08-10 Amorepacific Corporation Composition pour inhiber l'activation d'un récepteur des minéralocorticoïdes

Also Published As

Publication number Publication date
WO2002089757A3 (fr) 2003-03-13
DE10122342A1 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
DE10032964B4 (de) Verwendung von Kreatin in kosmetischen oder dermatologischen Zubereitungen
DE10121375B4 (de) Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE19933466A1 (de) Verwendung von Ectoinen als Antioxidantien oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen
EP1406585A2 (fr) Utilisation d'extraits de houblon et/ou de houblon et de malt dans des preparations cosmetiques ou dermatologiques pour prevenir et traiter des symptomes cutanes degeneratifs
DE10342212A1 (de) Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen Hautalterung
DE10136077A1 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
WO2002089757A2 (fr) Utilisation d'isoflavones dans des preparations cosmetiques ou dermatologiques
DE10048260A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
EP1311234A2 (fr) Substances permettant d'induire et d'intensifier les mecanismes de bronzage de la peau
EP1414401A1 (fr) Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques
WO2002087533A1 (fr) Utilisation d'extrait de trefle dans des preparations cosmetiques ou dermatologiques pour assurer la prophylaxie et le traitement d'eruptions cutanees degeneratives
DE19806889A1 (de) Verwendung von Acyl-Carnitin
WO2004022081A1 (fr) Preparations cosmetiques ou dermatologiques contenant des proteines antigel et/ou des glycoproteines antigel
EP1834630B1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et de la 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phényl}-6-(4-methoxyphenyl)-1,3,5-triazine
DE10212865A1 (de) 9-Retinal-alkanolamin Schiffsche Base und kosmetische oder dermatologische Formulierungen diese enthaltend
EP1311233B1 (fr) Substances permettant d'induire et d'intensifier les mecanismes de bronzage de la peau et formulations cosmetiques ou dermatologiques contenant ces substances
DE10316666B4 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10
WO2002087532A2 (fr) Formulations cosmetiques ou dermatologiques presentant une certaine teneur en sericoside et/ou en extraits de plantes contenant ce dernier
DE10131796A1 (de) Verwendung von Cardiolipin in kosmetischen oder dermatologischen Zubereitungen
DE10141681A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Anti-Freezing Proteinen und/oder Anti-freezing Glycoproteinen
DE19845266A1 (de) Verwendung von Butylhydroxytoluol zur Stabilisierung von Flavonen, Flavanonen bzw. Flavonoiden, synergistische Gemische aus Flavonen, Flavanonen bzw. Flavonoiden und Butylhydroxytoluol sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
DE10048261A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Pyridoxamin zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
EP0864313A2 (fr) Utilisation des benzophénones et leurs dérivés pour prévenir la décomposition induit par UV de dibenzoylméthane et ses dérivés
DE10225772A1 (de) Kosmetische oder dermatologische Formulierungen zur Pflege der Haut nach einem Sonnenbad oder einer Rasur
DE202006021296U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP